je.st
news
Medivation's Xtandi Easily Outperforms Casodex In Key Trial
2015-01-23 22:10:48| Biotech - Topix.net
Patients taking Xtandi had a median PFS of 15.7 months compared to 5.8 months in the Casodex group. I have written many articles about Medivation and why I believe their prostate cancer drug Xtandi is going to be a multi-billion dollar drug.
Tags: key
trial
easily
outperforms
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||